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Purpose: The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and tumor progression 
of colorectal cancer and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy 
has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted 
therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate 
the incidences of EGFR mutations in colorectal cancer patients in Korea. 
Methods: We retrospectively reviewed 58 colorectal cancer patients who underwent surgery between 2003 and 2006. We 
analyzed their EGFR mutations in four loci by DNA sequencing. In addition, we analyzed the correlation between the pres-
ence of EGFR mutation and patients’ clinicopathologic features.
Results: Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28 ± 11.18 years. Two patients 
(3.45%) were diagnosed as stage Tis, 7 patients (12.07%) as stage I, 24 patients (41.38%) as stage II, 20 patients (34.48%) as 
stage III, and 5 patients (8.62%) as stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected 
in 13 patients (22.41%, G→A transitions). No EGFR mutations were detected on exons 18, 19, and 21. EGFR mutation was 
increased in the earlier stage and in the absence of lymph node metastasis (P = 0.028). 
Conclusion: The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation 
was significantly increased in the earlier stage and in the absence of lymph node metastasis.
Keywords: Epidermal growth factor receptor; Mutation; Colorectal neoplasms
completely through surgical treatment, approximately 50% of pa-
tients were reported to show metastasis [1, 4]. Therefore, systemic 
chemotherapy, in addition to surgical treatment, has been widely 
applied to improve the survival rate, but existing chemotherapy 
combining oxaliplatin or irinotecan with 5-FU has not yet achieved 
a satisfactory survival rate for metastatic colorectal cancer patients 
[1, 4]. Thus, to enhance the treatment outcome for patients with 
resistance to existing antitumor agents, new therapies have drawn 
attention, and targeted therapy is representative in these terms [4].
Many targeted agents have been being developed. In particular, 
agents targeted at signal transduction for cell growth have been ac-
tively studied, and antitumor agents targeted at epidermal growth 
factor receptor (EGFR) are representative [5]. EGFR is a cell-sur-
face receptor for which expression increases in various malignant 
tumors, including colorectal cancer, and which affects cell growth 
and proliferation, metastasis, angiogenesis, and cell death through 
intracellular signal transduction [4, 5]. These days some agents tar-
geted at EGFR are being used, and they have contributed to im-
provements in the survival rate for colorectal cancer patients. How-
ever, patients with EGFR mutation have resistance to the therapy 
INTRODUCTION
Colorectal cancer is one of the malignant tumors that are found 
most frequently around the world [1, 2], and it newly occurs in 
around 500 thousand patients every year [3], ranking third among 
causes of death for cancer patients in Western countries [1, 3]. This 
tendency was also observed in South Korea. According to data from 
the Korea Central Cancer Registry published in 2008, the incidence 
and the mortality rates of colorectal cancer ranked third and fourth, 
respectively. Although about 70-80% at diagnosis can be cured 
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targeted at it, so checking for the existence of the mutation is help-
ful in deciding on an appropriate treatment. However, the incidence 
of the EGFR mutation in colorectal cancer patients has not yet been 
determined, and especially there are nearly no reports on the inci-
dence rate for Koreans. Therefore, this study was conducted to in-
vestigate the incidence rate of the EGFR mutation in colorectal can-
cer patients in Korea and to examine the correlation between clin-
ical and histopathologic characteristics and the existence of the 
mutation.
METHODS
This study investigated retrospectively 58 colorectal cancer patients 
surgically treated at the Surgery Department of Ewha Womans 
University Mokdong Hospital from January 2003 to December 
2006. There were no limitations on the gender and the age of the 
subjects, but patients undergoing preoperative chemotherapy or 
radiotherapy were excluded from this study. After surgery, all sub-
jects were diagnosed histopathologically as having a primary co-
lon or rectal adenocarcinoma, and their specimens obtained dur-
ing the surgery were analyzed.
To evaluate the mutation of EGFR, DNA was extracted from 
frozen sections of the specimens by using the QIAamp DNA Mini 
kit (Qiagen, Hilden, Germany) and following a conventional pro-
cedure [6]. Primers of exon 18 (codon 719), 19 (codon 746-750), 
20 (codon 787), and 21 (codon 858) of the EGFR gene were uti-
lized for amplification (Table 1). EGFR exons were amplified from 
100 ng of DNA through the polymerase chain reaction (PCR)         
in a 20 μL mixed solution including 2 μL of 10 × buffer (Roche, 
Mannheim, Germany), 1.7-2.5 of mmol/L MgCl2, 0.3 μM of each 
EGFR primer pair (Roche), 250 μmol/L of deoxynucleotide tri-
phosphates and 2.5 units of DNA polymerase (Roche). Amplifica-
tions involved a 5-minute initial denaturation step at 94°C, followed 
by 30 cycles of 1 minute at 94°C, 1 minute at 59°C, and 1 minute 
at 72°C, and a 10-minute final extension step at 72°C. All PCR prod-
ucts were separated with 2% agarose gel by using the QIAgen gel 
extraction kit (Qiagen), and they were used as templates for DNA 
sequencing. The sequencing was conducted by repeating 25 cycles 
of 10-second, 5-second and 4-minute treatments at 96°C, 50°C, 
and 60°C, respectively, with 20 ng of each separated PCR product 
in a 20 μL mixed solution for sequencing, including 8 μL of Big Dye 
Terminator v3.1 (Applied Biosystem, Foster City, CA, USA) and 
0.1 μmol/L of PCR primer, by using an ABI PRISM 3100 DNA 
Analyzer (Applied Biosystem). The data were analyzed with Se-
quencer 3.1.1 software (Applied Biosystems) to compare sequence 
variations. In addition, clinical characteristics, such as gender, age, 
tumor markers, survival and histopathologic characteristics, like 
the location, the stage and the differentiation of lesions and the 
existence of lymph node metastasis, were examined based on the 
medical records, and the correlations between these characteris-
tics and the EGFR mutation were investigated.
The correlations between the clinical and the histopathologic 
characteristics of the patients and the mutation were analyzed with 
Table 1. Primers used for amplification and sequencing of epidermal 
growth factor receptor genes
Amplified fragment Primer sequence
Exon 18 F: 5´-TCCAAATGAGCTGGCAAGTG
R: 5´-TCCCAAACACTCAGTGAAACAAA
Exon 19 F: 5´-ATGTGGCACCATCTCACAATTGCC
R: 5´-CCACACAGCAAAGCAGAAACTCAC
Exon 20 F: 5´-CATTCATGCGTCTTCACCTG
R: 5´-CATATCCCCATGGCAAACTC
Exon 21 F: 5´-GCTCAGAGCCTGGCATGAA
R: 5´-CATCCTCCCCTGCATGTGT
F, forward; R, reverse.
Table 2. Patient’s clinicopathologic features
Variable No. (%)
Total 58
Gender
   Male 35 (60.34)
   Female 23 (39.66)
Mean age (yr) 63.28 ± 11.18
CEA (ng/mL)
   ≤5 41 (70.69)
   >5 17 (29.31)
CA19-9 (U/mL)
   ≤27 51 (87.93)
   >27   7 (12.07)
Location
   Colon 37 (63.79)
   Rectum 21 (36.21)
Differentiation
   Well   8 (13.79)
   Moderate 45 (77.59)
   Poor 5 (8.62)
LN metastasis
   Absent 33 (56.90)
   Present 25 (43.10)
Stage
   Tis 2 (3.45)
   I   7 (12.07)
   II 24 (41.38)
   III 20 (34.48)
   IV 5 (8.62)
LN, lymph node; Tis, tumor in situ.Journal of The Korean Society of
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the Person’s the Fisher’s exact test and linear-by-linear association. 
After dividing the subjects into mutant-type and wild-type 
groups, we investigated the overall survival and the disease-free 
survival of each group by using the Kaplan-Meier method, and 
the survivals of the two groups were compared through a univari-
ate analysis using the log-rank test. The program used for the 
analysis was SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and a 
P-value of less than 0.05 was considered to be significant.
RESULTS
Clinical and histopathologic characteristics of the subjects
Totally, there were 58 subjects, consisting of 35 males (60.34%) and 
23 females (39.66%), and their mean age was 63.28 ± 11.18 years 
(range, 36 to 84 years). Preoperative CEA and CA19-9 levels were 
higher than the normal ranges in 17 (29.31%) and 7 (12.07%) sub-
jects, respectively (Table 2).
All of the subjects were surgically treated due to colorectal can-
cer, and after the surgery, they were diagnosed histopathologically 
as having a colon or a rectal adenocarcinoma. The lesions were 
located on the colon or the rectum in 37 (63.79%) and 21 (36.21%) 
patients, respectively. For histopathologic cell differentiation, 8 
(13.79%), 45 (77.59%), and 5 (8.62%) cases were well differenti-
ated, moderately differentiated and poorly differentiated, respec-
tively. Lymph node metastasis was found in 25 (43.10%) cases. 
Metastasis to other organs at diagnosis was occurred in 5 cases, 
and all of them showed metastasis to the liver. In addition, the re-
corded histopathologic stages were Tis and stage 1, 2, 3, and 4 in 2 
(3.45%), 7 (12.07%), 24 (41.38%), 20 (34.48%), and 5 (8.62%) cases, 
respectively (Table 2).
Incidence rate of the EGFR mutation
The EGFR mutations on exons 18 (codon 719), 19 (codon 746-
750), 20 (codon 787), and 21 (codon 858) of all specimens were 
analyzed through sequencing. According to the results, EGFR mu-
tations were observed on exon 20 in 13 (22.41%) patients. They 
were point mutations from ATG to ATA and produced amino acid 
substitution from methionine to isoleucine (Fig. 1). However, no 
mutations were found on exons 18, 19, and 21.
Correlation between the clinical and histopathologic 
characteristics and the EGFR mutation
Correlations between the clinical and histopathologic characteris-
tics and the EGFR mutation were investigated. When the existence 
of the EGFR mutation was assessed by classifying the stage into 
Tis-stage 2 and stage 3-4 groups, the mutations were found in 11 
out of 33 (56.90%) patients with colorectal cancer at Tis-stage 2 
and in 2 out of 25 (43.10%) patients with colorectal cancer at stage 
3-4. In the comparison between the two groups, the earlier stage 
group showed a significantly higher incidence rate of EGFR mu-
tation (P = 0.028).
EGFR-exon20-forward EGFR-exon20-reverse A B
Fig. 1. Sequencing results for the epithelial growth factor receptor 
(EGFR) mutation. Partial nucleotide sequences of the wild and the 
mutant in exon 20 of the EGFR gene. (A) Forward: transition of G to 
A (arrow), leading to the substitution of methionine for isoleucine 
and (B) Reverse: transition of C to T (arrow). 
Table 3. Relationship between the EGFR mutation and the clinico-
pathologic features
Variable Number EGFR  
mutation (%)
P-value
Age (yr) 0.74
   <60 19 5 (26.32)
   ≥60 39 8 (20.51)
Gender 0.21
   Male 35 10 (28.57)
   Female 23 3 (13.04)
CEA (ng/mL) 1
   5≤ 41 9 (21.95)
   >5 17 4 (23.53)
CA19-9 (U/mL) 1
   27≤ 51 12 (23.53)
   >27   7 1 (14.29)
Stage 0.028
   Tis-II 33 11 (33.33)
   III-IV 25 2 (8.00)
Location 0.751
   Colon 37 9 (24.32)
   Rectum 21 4 (19.05)
Differentiation 0.267
   Well   8 0 (0)
   Moderate 45 12 (26.67)
   Poor   5 1 (20.00)
LN metastasis 0.028
   Absent 33 11 (33.33)
   Present 25 2 (8.00)
EGFR, epithelial growth factor receptor; Tis, tumor in situ; LN, lymph node.Journal of The Korean Society of
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The subjects were also divided based on lymph node metastasis. 
Patients with and without metastasis were 25 (43.10%) and 33 
(56.90%), respectively, and EGFR mutations were found in 2 and 
11 cases, respectively. Therefore, patients without lymph node me-
tastasis recorded a significantly higher incidence rate for the mu-
tation (P = 0.028). However, gender, age, CEA and CA19-9 levels, 
and the location and the differentiation of lesions were not signifi-
cantly related to the existence of the EGFR mutation (Table 3).
Overall survival and disease-free survival were analyzed by clas-
sifying the subjects into two groups based on the existence of the 
EGFR mutation. The number of patients with the EGFR mutation 
was 13 (22.41%), and their average overall survival and disease-free 
survival were 57.85 ± 5.49 and 56.00 ± 6.47 months, respectively. 
The number of patients without the mutation was 45 (77.59%), and 
their overall survival and disease-free survival were 56.66 ± 2.79 
and 54.83 ± 3.24 months, respectively. When the overall survival 
and disease-free survival of the two groups were compared, there 
was no significant difference due to the EGFR mutation (Fig. 2).
DISCUSSION
EGFR, called as ErbB1, is a member of the ErbB family [7], and it 
is a transmembrane glycoprotein that forms part of the tyrosine 
kinase receptor protein. Its size is 170 kD, and it consists of 1186 
amino acid polypeptide chains [8]. The ErbB family is tyrosine ki-
nase receptors activated by different kinds of ligands, and it con-
sists of ErbB1 (EGFR, HER1), ErbB2 (HER2), ErbB3 (HER3), and 
ErbB4 (HER4). Each of them has extracellular, transmembrane 
and intracellular domains [4]. Their major ligands are EGF, TGF-α, 
amphiregulin and betacellulin [1]. If these ligands combine with 
domains, main intracellular signal transduction, such as the Ras/
Raf/MAPK pathway and the PI3K/Akt pathway, are activated 
through dimerization of receptors and continuous autophosphor-
ylation and influence the differentiation and the metastasis of tu-
mors, angiogenesis and cell death [1, 9].
The expression of EGFR is known to be increased for many ma-
lignant tumors, like head and neck cancer, stomach cancer, colorec-
tal cancer, prostate cancer, pancreatic cancer and lung cancer [10], 
and its over-expression was found in 65-75% of patients with ad-
vanced colorectal cancer [1]. Although many studies on the cor-
relation between the expression rate of EGFR and the prognosis 
for patients have been performed, no correlation has been deter-
mined. While for head and neck cancer, ovarian cancer, bladder 
cancer and esophageal cancer, its expression has been reported to 
be related to the survival rate of patients, for colorectal cancer, the 
correlation is not clear. According to most reports, the expression 
of EGFR in colorectal cancer patients is not related to clinical fac-
tors such as gender, age, the location and the differentiation of tu-
mors, and lymph node metastasis [11]. However, some studies in-
sist that the expression is associated with progression, differentia-
tion, lymph node metastasis and recurrence of colorectal cancer [5]. 
Therapies targeted at EGFR can be largely divided into two types: 
monoclonal antibodies blocking the interaction between ligands 
and extracellular domains and tyrosine kinase inhibitors hinder-
ing intracellular signal transduction pathways [1]. Monoclonal 
antibodies currently used are cetuximab and panitumumab, and 
they are reported to be effective in monotherapy or in combina-
tion therapy for colorectal cancer patients with resistance to irino-
tecan or oxaliplatin [1]. In addition, tyrosine kinase inhibitors are 
gefitinib and erlotinib, and they are applied mainly for small-cell 
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Fig. 2. Overall survival and disease-free survival according to epithelial growth factor receptor (EGFR) status. (A) There was no significant differ-
ence between the EGFR-wild group and the EGFR-mutant group as to overall survival (P = 0.8118). (B) EGFR mutational status was not asso-
ciated with any significant influence on disease-free survival (P = 0.8388). 
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lung carcinomas and are known to be ineffective in colorectal can-
cer patients [1].
Common antitumor agents used for colorectal cancer are 5-FU, 
oxaliplatin and irinotecan. As signal transduction pathways caused 
by EGFR and K-ras are known to be related to the pathogenesis of 
colorectal cancer, a therapy targeted at EGFR is applied when there 
is resistance to existing antitumor agents and EGFR is expressed. 
However, some studies reporting resistance to these agents [12] 
suggested that the resistance was associated with a mutation of 
EGFR, so efforts have been made to investigate the incidence of 
patients with the mutation and to develop therapies fitting them.
Most of studies on EGFR mutation have been conducted with 
small-cell lung carcinomas, and the mutation was reported to be 
observed in 45% of the cases [13]. According to studies by regions, 
the EGFR mutation was found in 28% of small-cell lung carcinoma 
patients in Greece [14], and the rate of the mutation was 15% in 
Korea [15]. Another study published in Korea reported a higher 
incidence rate of 24% and revealed no significant correlation of 
the EGFR mutation with clinicopathologic characteristics, includ-
ing age, gender, stage and differentiation [6]. Unlike small-cell lung 
carcinomas, for which a correlation with the EGFR mutation has 
been reported in many studies, for colorectal cancer, only the in-
cidence rate of the mutation has been reported, and there has been 
nearly no study on its correlation with clinicopathologic charac-
teristics [13, 16]. Some research published in Western countries 
found that the incidence of the EGFR mutation in colorectal can-
cer patients was very low. Barber et al. [16] reported that it was 
0.34% of 293 patients, and Ogino et al. [17] reported that the mu-
tation on exon 18 was observed in one (3.3%) of 30 patients. Mean-
while, studies in Japan showed slightly higher incidence rates com-
pared to Western countries. Nagahara et al. [13] revealed that EGFR 
mutations were found in four (12%) of 33 colorectal cancer patients 
and that the mutations had occurred on exon 19 in 2 patients and 
on exon 20 in 2 patients. Our study investigated the incidence rate 
of the EGFR mutation for colorectal cancer patients in Korea and 
found that 13 out of 58 (22.4%) had the mutation on exon 20. The 
patients at earlier stage and with no lymph node metastasis tended 
to show a significantly higher incidence rate of the mutation, but 
the overall survival and the disease-free survival were not signifi-
cantly different. The correlations of the mutation with clinicopath-
ologic characteristics, such as gender, age, CEA and CA19-9 levels, 
and the location and the differentiation of lesions, were also inves-
tigated, but no significant correlations were found.
This study had some limitations. The sample size was small, and 
the data were analyzed retrospectively. The subjects were patients 
in a single medical institution, so the results may not apply to all 
colorectal cancer patients. Because the subjects did not undergo 
the same treatments, the correlation between the EGFR mutation 
and clinical outcomes could not be evaluated properly. However, 
considering that there have been no studies on the EGFR muta-
tion in colorectal cancer patients, our study is meaningful as it in-
vestigates the incidence rate of the mutation.
The incidence rate of the EGFR mutation in colorectal cancer 
patients in Korea was 22.41%, and it was significantly higher in 
the patients at earlier stage and without lymph node metastasis. If 
a study with a larger population is conducted in the future, it will 
produce more meaningful outcomes. In addition, examination to 
check the EGFR mutation before targeted therapy for colorectal 
cancer patients is necessary.
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